Mitralign Inc., a Tewksbury, Mass.-based cardiac device company, has closed $35m in Series D financing.
The round was led by Forbion Capital Partners, with participation from Saints Venture Capital, Oxford Bioscience Partners, Triathlon Medical Ventures, Medtronic Corporation, Johnson & Johnson Development Corp., Orchestra Medical Ventures, Oakwood Medical Investors, Palisade Capital Management and Giza Venture Capital.
Led by Rick Geoffrion, CEO, Mitralign is currently conducting clinical studies to evaluate its innovative catheter-based mitral valve repair technology for first-line percutaneous and trans-apical treatment of Functional Mitral Regurgitation (FMR).
The company intends to use the capital to complete the CE Mark study, secure the CE Mark, and initiate sales in the EU.
Led by Rick Geoffrion, CEO, Mitralign is currently conducting clinical studies to evaluate its innovative catheter-based mitral valve repair technology for first-line percutaneous and trans-apical treatment of Functional Mitral Regurgitation (FMR).
FinSMEs
16/05/2012